Post-HCT outcomes: univariate analysis
| Outcome event . | Matched sibling donor, incidence (95% CI) . | Well-matched URD, incidence (95% CI) . | Partially-matched URD, incidence (95% CI) . | P, overall . | P, MSD vs well-matched URD . | P, well-matched URD vs partially-matched URD . |
|---|---|---|---|---|---|---|
| Acute GVHD, grades 2-4, 100 d | 38 (31-44) | 54 (48-60)* | 52 (42-61) | < .001 | < .001 | NS |
| Chronic GVHD† | ||||||
| 1 y | 39 (32-46) | 54 (47-61)* | 50 (37-61) | .007 | .002 | .53 |
| 3 y | 43 (36-50) | 59 (52-66)* | 54 (41-66) | .007 | .002 | .50 |
| TRM | ||||||
| 100 d | 8 (5-12) | 11 (7-15) | 26 (18-35) | < .001 | NS | .001 |
| 3 y | 21 (16-27) | 26 (21-32) | 47 (37-56) | < .001 | NS | < .001 |
| Relapse | ||||||
| 1 y | 29 (23-35) | 35 (29-41) | 20 (13-29) | .015 | NS | .004 |
| 3 y | 37 (31-44) | 40 (33-46) | 24 (16-33) | .013 | NS | .004 |
| LFS | ||||||
| 1 y | 54 (47-61) | 46 (39-52) | 37 (27-46) | .01 | .06 | .14 |
| 3 y | 42 (35-48) | 34 (28-41) | 29 (20-39) | .08 | .11 | NS |
| OS | ||||||
| 1 y | 63 (56-69) | 54 (48-60) | 42 (32-51) | .001 | .06 | .03 |
| 3 y | 45 (38-52) | 37 (31-44) | 31 (22-41) | .07 | .13 | NS |
| Outcome event . | Matched sibling donor, incidence (95% CI) . | Well-matched URD, incidence (95% CI) . | Partially-matched URD, incidence (95% CI) . | P, overall . | P, MSD vs well-matched URD . | P, well-matched URD vs partially-matched URD . |
|---|---|---|---|---|---|---|
| Acute GVHD, grades 2-4, 100 d | 38 (31-44) | 54 (48-60)* | 52 (42-61) | < .001 | < .001 | NS |
| Chronic GVHD† | ||||||
| 1 y | 39 (32-46) | 54 (47-61)* | 50 (37-61) | .007 | .002 | .53 |
| 3 y | 43 (36-50) | 59 (52-66)* | 54 (41-66) | .007 | .002 | .50 |
| TRM | ||||||
| 100 d | 8 (5-12) | 11 (7-15) | 26 (18-35) | < .001 | NS | .001 |
| 3 y | 21 (16-27) | 26 (21-32) | 47 (37-56) | < .001 | NS | < .001 |
| Relapse | ||||||
| 1 y | 29 (23-35) | 35 (29-41) | 20 (13-29) | .015 | NS | .004 |
| 3 y | 37 (31-44) | 40 (33-46) | 24 (16-33) | .013 | NS | .004 |
| LFS | ||||||
| 1 y | 54 (47-61) | 46 (39-52) | 37 (27-46) | .01 | .06 | .14 |
| 3 y | 42 (35-48) | 34 (28-41) | 29 (20-39) | .08 | .11 | NS |
| OS | ||||||
| 1 y | 63 (56-69) | 54 (48-60) | 42 (32-51) | .001 | .06 | .03 |
| 3 y | 45 (38-52) | 37 (31-44) | 31 (22-41) | .07 | .13 | NS |
Data are cumulative incidence (for GVHD, TRM, and relapse) or Kaplan-Meier estimates (LFS and OS; 95% confidence interval) for outcomes.
NS indicates pairwise comparisons that were not statistically significant (P > .15).
Significantly different (P < .05) outcomes (acute and chronic GVHD) between MSD and well-matched URD. All other comparisons between these 2 subgroups were NS.
Calculated for patients surviving 100 days after transplantation.